Diabetes, Vol 37, Issue 6 780-786, Copyright © 1988 by American Diabetes Association

ARTICLES

Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo

M Trovati, G Anfossi, F Cavalot, P Massucco, E Mularoni and G Emanuelli
Cattedra di Clinica Medica Generale e Terapia Medica III, University of Turin, San Luigi Gonzaga Hospital, Italy.

The aim of this study was to investigate the influence of insulin on platelet function, both in vitro and in vivo. For the in vitro investigation, we evaluated whether insulin affects platelet function at a physiological hormone concentration by incubating the platelet-rich plasma (PRP) of fasting subjects with human regular insulin at the final concentration of 40 microU/ml for 30 min; we observed a significant reduction of platelet sensitivity to all the aggregating agents employed, i.e., ADP, platelet-activating factor (PAF), epinephrine, collagen, and Na+ arachidonate. To investigate whether the insulin effect on platelets is dose dependent, we incubated the PRP of fasting subjects with different concentrations of human regular insulin (40, 80, 120, and 160 microU/ml) for 5 min, and we observed that the insulin-induced reduction of platelet sensitivity to aggregating agents is a dose-dependent phenomenon. Furthermore, the comparison between the platelet responses after 5 and 30 min of incubation with insulin showed that the insulin effect on platelet aggregation is time dependent. The lack of specificity of its inhibiting activity suggests that insulin does not interfere with the initial binding of each aggregating agent at specific sites but does influence a common step of platelet aggregation. Our study rules out the possibility that insulin reduces platelet-function-modifying intraplatelet cAMP levels or thromboxane A2 production, because this hormone decreases the platelet concentrations of cAMP--a phenomenon that, per se, promotes platelet aggregation--and does not modify collagen or Na+ arachidonate--induced platelet production of thromboxane A2, measured by radioimmunoassay of its stable-metabolite thromboxane B2.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. Bonora, S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, J. B. Meigs, R. C. Bonadonna, and M. Muggeo Insulin Resistance as Estimated by Homeostasis Model Assessment Predicts Incident Symptomatic Cardiovascular Disease in Caucasian Subjects From the General Population: The Bruneck Study Diabetes Care, February 1, 2007; 30(2): 318 - 324. [Abstract] [Full Text] [PDF]

				A. Lepantalo, K. S Virtanen, J. Heikkila, U. Wartiovaara, and R. Lassila Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions Eur. Heart J., March 2, 2004; 25(6): 476 - 483. [Abstract] [Full Text] [PDF]

				V. Randriamboavonjy, J. Schrader, R. Busse, and I. Fleming Insulin Induces the Release of Vasodilator Compounds From Platelets by a Nitric Oxide-G Kinase-VAMP-3-dependent Pathway J. Exp. Med., February 2, 2004; 199(3): 347 - 356. [Abstract] [Full Text] [PDF]

				E. Bonora, G. Formentini, F. Calcaterra, S. Lombardi, F. Marini, L. Zenari, F. Saggiani, M. Poli, S. Perbellini, A. Raffaelli, et al. HOMA-Estimated Insulin Resistance Is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic Subjects: Prospective data from the Verona Diabetes Complications Study Diabetes Care, July 1, 2002; 25(7): 1135 - 1141. [Abstract] [Full Text] [PDF]

				J. Westerbacka, H. Yki-Jarvinen, A. Turpeinen, A. Rissanen, S. Vehkavaara, M. Syrjala, and R. Lassila Inhibition of Platelet-Collagen Interaction: An In Vivo Action of Insulin Abolished by Insulin Resistance in Obesity Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 167 - 172. [Abstract] [Full Text] [PDF]

				A. I. Vinik, T. Erbas, T. S. Park, R. Nolan, and G. L. Pittenger Platelet Dysfunction in Type 2 Diabetes Diabetes Care, August 1, 2001; 24(8): 1476 - 1485. [Abstract] [Full Text] [PDF]

				Z. Chen, S. Ishibashi, S. Perrey, J.-i. Osuga, T. Gotoda, T. Kitamine, Y. Tamura, H. Okazaki, N. Yahagi, Y. Iizuka, et al. Troglitazone Inhibits Atherosclerosis in Apolipoprotein E-Knockout Mice : Pleiotropic Effects on CD36 Expression and HDL Arterioscler. Thromb. Vasc. Biol., March 1, 2001; 21(3): 372 - 377. [Abstract] [Full Text] [PDF]

				J. Westerbacka, I. Wilkinson, J. Cockcroft, T. Utriainen, S. Vehkavaara, and H. Yki-Jarvinen Diminished Wave Reflection in the Aorta : A Novel Physiological Action of Insulin on Large Blood Vessels Hypertension, May 1, 1999; 33(5): 1118 - 1122. [Abstract] [Full Text] [PDF]

				E. Bonora, J. Willeit, S. Kiechl, F. Oberhollenzer, G. Egger, R. Bonadonna, and M. Muggeo Relationship Between Insulin and Carotid Atherosclerosis in the General Population : The Bruneck Study Stroke, June 1, 1997; 28(6): 1147 - 1152. [Abstract] [Full Text]

				M. Ishida, T. Ishida, N. Ono, H. Matsuura, M. Watanabe, G. Kajiyama, M. Kambe, and T. Oshima Effects of Insulin on Calcium Metabolism and Platelet Aggregation Hypertension, August 1, 1996; 28(2): 209 - 212. [Abstract] [Full Text]

				K. Shinozaki, M. Suzuki, M. Ikebuchi, H. Takaki, Y. Hara, M. Tsushima, and Y. Harano Insulin Resistance Associated With Compensatory Hyperinsulinemia as an Independent Risk Factor for Vasospastic Angina Circulation, October 1, 1995; 92(7): 1749 - 1757. [Abstract] [Full Text]